• 28 March 2016

    Sonendo announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the next generation of it’s GentleWave® System. This clearance provides the endodontist with the choice of using the default treatment cycles or reducing the treatment cycles as desired based on their evaluation of a tooth for root canal treatment using the GentleWave System. This most recent FDA clearance is in alignment with Sonendo’s commitment to develop products that improve clinical efficacy, treatment efficiency, and practice economy for the endodontist. Randy W. Garland, DDS, Garland Endodontics, Encinitas, CA, stated “The increase versatility of this upgrade gives the Endodontist control to treat the variety of clinical situations we are presented with.”

  • 17 March 2016

    TopiVert Pharma Ltd (“TopiVert” or the “Company”), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory diseases of the gastrointestinal tract and eye, today announced positive Phase I study results for TOP1288, its lead compound for the treatment of ulcerative colitis (UC). TopiVert will present the Phase I study data at the 11th Congress of ECCO in Amsterdam on Friday 18 March 2016. 

  • 9 March 2016

    Funding will support further Clinical Evaluation and Market Access for 4Tech TriCinch™, a breakthrough technology for Transcatheter Valve Repair (TTVR).

  • 7 March 2016

    InDex Pharmaceuticals AB today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a phase IIb study with its lead drug candidate cobitolimod (Kappaproct®) in patients with moderate to severe ulcerative colitis (UC).

  • 22 February 2016

    Imperial Innovations has led a £13.5 million investment round in Precision Ocular Ltd (Precision Ocular), a London-based retinal therapeutics company.